Page 51 - Read Online

with 32 tables, 2nd rev. ed. Berlin: Springer, 2006. for detection of gastrointestinal carcinoid tumors. Radiology
16. Elgazzar AH, Kazem N. Biological effects of ionizing radiation. 2001;220:373-80.
The pathophysiologic basis of nuclear medicine, Elgazzar, AH, ed. 34. Tomimaru Y, Eguchi H, Tatsumi M, Kim T, Hama N, Wada H,
Berlin, Germany: Springer-Verlag, 2015; pp. 369-70. Kawamoto K, Kobayashi S, Morii E, Mori M, Doki Y, Nagano
17. Warburg O. On respiratory impairment in cancer cells. Science H. Clinical utility of 2-[18F] fluoro-2-deoxy-D-glucose positron
1956;124:269-70. emission tomography in predicting World Health Organization grade
18. Brock CS, Meikle SR, Price P. Does fluorine-18 fluorodeoxyglucose in pancreatic neuroendocrine tumors. Surgery 2015;157:269-76.
metabolic imaging of tumours benefit oncology? Eur J Nucl Med 35. Klimstra DS, Modlin IR, Coppola D, Lloyd RV, Suster S. The pathologic
1997;24:691-705. classification of neuroendocrine tumors: a review of nomenclature,
19. Shankar LK, Hoffman JM, Bacharach S, Graham MM, Karp J, grading, and staging systems. Pancreas 2010;39:707-12.
Lammertsma AA, Larson S, Mankoff DA, Siegel BA, den Abbeele 36. Lee CS. Differences in cell proliferation and prognostic
AV, Yap J, Sullivan D. Consensus recommendations for the use of significance of proliferating cell nuclear antigen and Ki-67
18F-FDG PET as an indicator of therapeutic response in patients in antigen immunoreactivity in in situ and invasive carcinomas of the
national cancer institute trials. J Nucl Med 2006;47:1059-66. extrahepatic biliary tract. Cancer 1996;78:1881-7.
20. Hofmann M, Maecke H, Börner A, Weckesser E, Schöffski P, 37. Minn H, Joensuu H, Ahonen A, Klemi P. Fluorodeoxyglucose
Oei M, Schumacher J, Henze M, Heppeler A, Meyer G, Knapp imaging: a method to assess the proliferative activity of human
W. Biokinetics and imaging with the somatostatin receptor PET cancer in vivo. Comparison with DNA flow cytometry in head and
radioligand 68Ga-DOTATOC: preliminary data. Eur J Nucl Med neck tumors. Cancer 1988;61:1776-81.
2001;28:1751-7. 38. Kayani I, Bomanji JB, Groves A, Conway G, Gacinovic S, Win T,
21. Poeppel TD, Binse I, Petersenn S, Lahner H, Schott M, Antoch G, Dickson J, Caplin M, Ell PJ. Functional imaging of neuroendocrine
68
Brandau W, Bockisch A, Boy C. 68Ga-DOTATOC versus 68Ga- tumors with combined PET/CT using Ga-DOTATATE (DOTA-
DOTATATE PET/CT in functional imaging of neuroendocrine DPhe1,Tyr3-octreotate) and F-FDG. Cancer 2008;112:2447-55.
18
tumors. J Nuc Med 2011;52:1864-70. 39. Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A.
22. Ambrosini V, Campana D, Bodei L, Nanni C, Castellucci P, Allegri V, 18F-fluorodeoxyglucose positron emission tomography predicts
Montini GC, Tomassetti P, Paganelli G, Fanti S. 68Ga-DOTANOC survival of patients with neuroendocrine tumors. Clin Cancer Res
PET/CT clinical impact in patients with neuroendocrine tumors. J 2010;16:978-85.
Nucl Med 2010;51:669-73. 40. Partelli S, Rinzivillo M, Maurizi A, Panzuto F, Salgarello M,
23. Virgolini I, Ambrosini V, Bomanji JB, Baum RP, Fanti S, Gabriel Polenta V, Delle Fave G, Falconi M. The role of combined Ga-
M, Papathanasiou ND, Pepe G, Oyen W, Cristoforo CD, Chiti DOTANOC and (18)FDG PET/CT in the management of patients
A. Procedure guidelines for PET/CT tumour imaging with with pancreatic neuroendocrine tumors. Neuroendocrinology
68Ga-DOTA-conjugated peptides: 68Ga-DOTA-TOC, 68Ga- 2014;100:293-9.

DOTA-NOC, 68Ga-DOTA-TATE. Eur J Nucl Med Mol Imaging 41. Treglia G, Castaldi P, Rindi G, Giordano A, Rufini V. Diagnostic
2010;37:2004-10. performance of Gallium-68 somatostatin receptor PET and PET/CT
24. Yang J, Kan Y, Ge BH, Yuan L, Li C, Zhao W. Diagnostic role in patients with thoracic and gastroenteropancreatic neuroendocrine
of Gallium-68 DOTATOC and Gallium-68 DOTATATE PET in tumours: a meta-analysis. Endocrine 2012;42:80-7.
patients with neuroendocrine tumors: a meta-analysis. Acta Radiol 42. Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij
2014;55:389-98. PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC.
25. Gabriel M, Decristoforo C, Kendler D, Dobrozemsky G, Heute Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]-
D, Uprimny C, Kovacs P, Guggenberg EV, Bale R, Virgolini IJ. and [123I-Tyr3]-octreotide: the Rotterdam experience with more
68Ga-DOTA-Tyr3-Octreotide PET in neuroendocrine tumors: than 1000 patients. Eur J Nucl Med 1993;20:716-31.
comparison with somatostatin receptor scintigraphy and CT. J Nucl 43. Frilling A, Malago M, Martin H, Broelsch CE. Use of somatostatin
Med 2007;48:508-18. receptor scintigraphy to image extrahepatic metastases of
26. Fisseler-Eckhoff A, Demes M. Neuroendocrine tumors of the lung. neuroendocrine tumors. Surgery 1998;124:1000-4.
Cancers 2012;4:777-98. 44. Nilsson O, Kӧlby L, Wängberg B, Wigander A, Billig H, William-
27. Erasmus JJ, McAdams HP, Patz EF, Coleman RE, Ahuja V, Olsson L, Fjälling M, Forssell-Aronsson E, Ahlman H. Comparative
Goodman PC. Evaluation of primary pulmonary carcinoid tumors studies on the expression of somatostatin receptor subtypes, outcome
using FDG PET. AJR Am J Roentgenol 1998;170:1369-73. of octreotide scintigraphy and response to octreotide treatment in
28. Kayani I, Conry BG, Groves AM, Win T, Dickson J, Caplin M, patients with carcinoid tumours. Br J Cancer 1998;77:632-7.
Bomanji JN. A comparison of 68Ga-DOTATATE and F-FDG 45. Gibril F, Reynolds JC, Doppman JL, Chen CC, Venzon DJ,
18
PET/CT in pulmonary neuroendocrine tumors. J Nucl Med Termanini B, Weber HC, Stewart CA, Jensen RT. Somatostatin
2009;50:1927-32. receptor scintigraphy: its sensitivity compared with that of other
29. Pape UF, Böhmig M, Berndt U, Tiling N, Wiedenmann B, Plöckinger imaging methods in detecting primary and metastatic gastrinomas.
U. Survival and clinical outcome of patients with neuroendocrine A prospective study. Ann Intern Med 1996;125:26-34.
tumors of the gastroenteropancreatic tract in a german referral 46. Dromain C, de Baere T, Lumbroso J, Caillet H, Laplanche A, Boige
center. Ann N Y Acad Sci 2004;1014:222-33. V, Ducreux M, Duvillard P, Elias D, Schlumberger M, Sigal R,
30. Khan S, Lloyd C, Szyszko T, Win Z, Rubello D, Al-Nahhas A. PET Baudin E. Detection of liver metastases from endocrine tumors:
imaging in endocrine tumours. Minerva Endocrinol 2008;33:41-52. a prospective comparison of somatostatin receptor scintigraphy,
31. Pandit N, Gonen M, Krug L, Larson S. Prognostic value of [18 F] computed tomography, and magnetic resonance imaging. J Clin
FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Oncol 2005;23:70-8.
Imaging 2003;30:78-84. 47. Al-Nahhas A, Win Z, Szyszko T, Singh A, Nanni C, Fanti S, Rubello
32. Daniels CE, Lowe VJ, Aubry MC, Allen MS, Jett JR. The utility of D. Gallium-68 PET: a new frontier in receptor cancer imaging.
fluorodeoxyglucose positron emission tomography in the evaluation Anticancer Res 2007;27:4087-94.
of carcinoid tumors presenting as pulmonary nodules. Chest 48. Buchmann I, Henze M, Engelbrecht S, Eisenhut M, Runz A, Schäfer
2007;131:255-60. M, Schilling T, Haufe S, Herrmann T, Haberkorn U. Comparison of
33. Hoegerle S, Altehoefer C, Ghanem N, Koehler G, Waller CF, 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT
Scheruebl H, Moser E, Nitzsche E. Whole-body 18F Dopa PET in patients with neuroendocrine tumours. Eur J Nucl Med Mol
Journal of Cancer Metastasis and Treatment ¦ Volume 2 ¦ August 31, 2016 ¦ 327